Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism

Science

Volumn 364, Issue 6445, 2019, Pages

  Rekdal, Vayu Maini ^a   Bess, Elizabeth N ^b,c   Bisanz, Jordan E ^b   Turnbaugh, Peter J ^b,d   Balskus, Emily P ^a  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHAN ZUCKERBERG BIOHUB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; DOPAMINE; LEVODOPA; META TYRAMINE; OXYGENASE; TYROSINE DECARBOXYLASE; 3-FLUORO-ALPHA-FLUOROMETHYLTYROSINE; ANTIPARKINSON AGENT; BACTERIAL PROTEIN; TYROSINE;

AMINO ACID; BIOAVAILABILITY; CHEMICAL REACTION; DRUG; ENZYME; ENZYME ACTIVITY; INHIBITION; METABOLISM; MICROBIAL ACTIVITY; MICROORGANISM; NERVOUS SYSTEM DISORDER; TRANSFORMATION;

ARTICLE; DECARBOXYLATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG RESPONSE; EGGERTHELLA LENTA; ENTEROCOCCUS FAECALIS; EX VIVO STUDY; HUMAN; INTESTINE FLORA; MOLECULAR MECHANICS; NONHUMAN; ORGANISMAL INTERACTION; PARKINSON DISEASE; PRIORITY JOURNAL; ACTINOBACTERIA; ANIMAL; BACTERIAL GENOME; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HELA CELL LINE; MALE; METABOLISM;

BACTERIA (MICROORGANISMS); EGGERTHELLA LENTA; ENTEROCOCCUS FAECALIS; MUS;

ACTINOBACTERIA; ANIMALS; ANTIPARKINSON AGENTS; BACTERIAL PROTEINS; DECARBOXYLATION; DOPAMINE; ENTEROCOCCUS FAECALIS; GASTROINTESTINAL MICROBIOME; GENOME, BACTERIAL; HELA CELLS; HUMANS; LEVODOPA; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE, INBRED BALB C; TYROSINE; TYROSINE DECARBOXYLASE;

EID: 85067609952     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aau6323     Document Type: Article

References (63)

1. G. Sharon, T. R. Sampson, D. H. Geschwind, S. K. Mazmanian, The central nervous system and the gut microbiome. Cell 167, 915–932 (2016). doi: 10.1016/j.cell.2016.10.027; pmid: 27814521
2. T. R. Sampson et al., Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167, 1469–1480.e12 (2016). doi: 10.1016/j.cell.2016.11.018; pmid: 27912057
3. F. Scheperjans et al., Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. Disord. 30, 350–358 (2015). doi: 10.1002/mds.26069; pmid: 25476529
4. M. M. Unger et al., Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016). doi: 10.1016/j.parkreldis.2016.08.019; pmid: 27591074
5. J. R. Bedarf et al., Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients. Genome Med. 9, 39 (2017). doi: 10.1186/s13073-017-0428-y; pmid: 28449715
6. E. M. Hill-Burns et al., Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 32, 739–749 (2017). doi: 10.1002/ mds.26942; pmid: 28195358
7. T. Minato et al., Progression of Parkinson’s disease is associated with gut dysbiosis: Two-year follow-up study. PLOS ONE 12, e0187307 (2017). doi: 10.1371/ journal.pone.0187307; pmid: 29091972
8. V. A. Petrov et al., Analysis of gut microbiota in patients with Parkinson’s disease. Bull. Exp. Biol. Med. 162, 734–737 (2017). doi: 10.1007/s10517-017-3700-7; pmid: 28429209
9. A. Heintz-Buschart et al., The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 33, 88–98 (2018). doi: 10.1002/mds.27105; pmid: 28843021
10. O. Hornykiewicz, L-DOPA. J. Parkinsons Dis. 7 (s1), S3–S10 (2017). doi: 10.3233/JPD-179004; pmid: 28282813
11. P. S. Papavasiliou et al., Levodopa in Parkinsonism: Potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med. 286, 8–14 (1972). doi: 10.1056/ NEJM197201062860102; pmid: 4550085
12. K. F. Gey, A. Pletscher, Distribution and metabolism of DL-3,4-dihydroxy[2-14C]-phenylalanine in rat tissues. Biochem. J. 92, 300–308 (1964). doi: 10.1042/bj0920300; pmid: 5838073
13. S. Bergmann et al., The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism. Br. J. Clin. Pharmacol. 1, 417–424 (1974). doi: 10.1111/ j.1365-2125.1974.tb00280.x; pmid: 22454921
14. M. M. Goldenberg, Medical management of Parkinson’s disease. P&T 33, 590–606 (2008). pmid: 19750042
15. A. C. Whitfield, B. T. Moore, R. N. Daniels, Classics in chemical neuroscience: Levodopa. ACS Chem. Neurosci. 5, 1192–1197 (2014). doi: 10.1021/cn5001759; pmid: 25270271
16. SINEMET CR, (carbidopa-levodopa) [package insert]. Princeton: Bristol-Myers Squibb Company, NJ; 2008.
17. R. Gray et al., Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): A large, open-label, pragmatic randomised trial. Lancet 384, 1196–1205 (2014). doi: 10.1016/S0140-6736(14)60683-8; pmid: 24928805
18. P. Spanogiannopoulos, E. N. Bess, R. N. Carmody, P. J. Turnbaugh, The microbial pharmacists within us: A metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273–287 (2016). doi: 10.1038/nrmicro.2016.17; pmid: 26972811
19. H. Hashim et al., Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease. PLOS ONE 9, e112330 (2014). doi: 10.1371/journal.pone.0112330; pmid: 25411976
20. A. Fasano et al., The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov. Disord. 28, 1241–1249 (2013). doi: 10.1002/mds.25522; pmid: 23712625
21. F. Deeds, A. N. Booth, F. T. Jones, Methylation and dehydroxylation of phenolic compounds by rats and rabbits. J. Biol. Chem. 225, 615–621 (1957). pmid: 13416264
22. B. R. Goldin, M. A. Peppercorn, P. Goldman, Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J. Pharmacol. Exp. Ther. 186, 160–166 (1973). pmid: 4723308
23. M. Sandler, B. L. Goodwin, C. R. Ruthven, D. B. Calne, Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man. Nature 229, 414–415 (1971). doi: 10.1038/229414a0; pmid: 4926994
24. M. Sandler, C. R. Ruthven, B. L. Goodwin, K. R. Hunter, G. M. Stern, Variation of levodopa metabolism with gastrointestinal absorption site. Lancet 1, 238–240 (1974). doi: 10.1016/S0140-6736(74)92547-1; pmid: 4130247
25. P. Goldman, M. A. Peppercorn, B. R. Goldin, Metabolism of drugs by microorganisms in the intestine. Am. J. Clin. Nutr. 27, 1348–1355 (1974). doi: 10.1093/ajcn/27.11.1348; pmid: 4155602
26. B. L. Goodwin, C. R. J. Ruthven, G. S. King, M. Sandler, B. G. S. Leask, Metabolism of 3, 4-dihydroxyphenylalanine, its metabolites and analogues in vivo in the rat: Urinary excretion pattern. Xenobiotica 8, 629–651 (1978). doi: 10.3109/ 00498257809069575; pmid: 716472
27. A. C. Eliot, J. F. Kirsch, Pyridoxal phosphate enzymes: Mechanistic, structural, and evolutionary considerations. Annu. Rev. Biochem. 73, 383–415 (2004). doi: 10.1146/ annurev.biochem.73.011303.074021; pmid: 15189147
28. H. Zhu et al., Crystal structure of tyrosine decarboxylase and identification of key residues involved in conformational swing and substrate binding. Sci. Rep. 6, 27779 (2016). doi: 10.1038/srep27779; pmid: 27292129
29. V. Ladero et al., Is the production of the biogenic amines tyramine and putrescine a species-level trait in enterococci? Food Microbiol. 30, 132–138 (2012). doi: 10.1016/ j.fm.2011.12.016; pmid: 22265293
30. F. Lebreton et al., Tracing the Enterococci from Paleozoic origins to the hospital. Cell 169, 849–861.e13 (2017). doi: 10.1016/j.cell.2017.04.027; pmid: 28502769
31. H. Blashcko, Substrate specificity of amino acid decarboxylases. Biochim. Biophys. Acta 4, 130–137 (1950). doi: 10.1016/0006-3002(50)90016-3; pmid: 15403918
32. N. Connil et al., Identification of the Enterococcus faecalis tyrosine decarboxylase operon involved in tyramine production. Appl. Environ. Microbiol. 68, 3537–3544 (2002). doi: 10.1128/AEM.68.7.3537-3544.2002; pmid: 12089039
33. J. Kollonitsch et al., Selective inhibitors of biosynthesis of aminergic neurotransmitters. Nature 274, 906–908 (1978). doi: 10.1038/274906a0; pmid: 683331
34. T. Børresen, N. K. Klausen, L. M. Larsen, H. Sørensen, Purification and characterisation of tyrosine decarboxylase and aromatic-L-amino-acid decarboxylase. Biochim. Biophys. Acta 993, 108–115 (1989). doi: 10.1016/0304-4165(89)90149-9; pmid: 2508758
35. F. Liu et al., Heterologous expression and characterization of tyrosine decarboxylase from Enterococcus faecalis R612Z1 and Enterococcus faecium R615Z1. J. Food Prot. 77, 592–598 (2014). doi: 10.4315/0362-028X.JFP-13-326; pmid: 24680070
36. E. Pessione et al., First evidence of a membrane-bound, tyramine and beta-phenylethylamine producing, tyrosine decarboxylase in Enterococcus faecalis: A two-dimensional electrophoresis proteomic study. Proteomics 9, 2695–2710 (2009). doi: 10.1002/pmic.200800780; pmid: 19405032
37. S. Allenmark, B. Servenius, Characterization of bacterial L-(-)-tyrosine decarboxylase by isoelectric focusing and gel chromatography. J. Chromatogr. 153, 238–245 (1978). doi: 10.1016/S0021-9673(00)89878-7; pmid: 96122
38. S. P. van Kessel et al., Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat. Commun. 10, 310 (2019). doi: 10.1038/ s41467-019-08294-y; pmid: 30659181
39. W. B. Abrams, C. B. Coutinho, A. S. Leon, H. E. Spiegel, Absorption and metabolism of levodopa. JAMA 218, 1912–1914 (1971). doi: 10.1001/jama.1971.03190260028007; pmid: 5171067
40. S. A. Adibi, D. W. Mercer, Protein digestion in human intestine as reflected in luminal, mucosal, and plasma amino acid concentrations after meals. J. Clin. Invest. 52, 1586–1594 (1973). doi: 10.1172/JCI107335; pmid: 4718954
41. M. Perez et al., Tyramine biosynthesis is transcriptionally induced at low pH and improves the fitness of Enterococcus faecalis in acidic environments. Appl. Microbiol. Biotechnol. 99, 3547–3558 (2015). doi: 10.1007/s00253-014-6301-7; pmid: 25529314
42. J. Fallingborg, Intraluminal pH of the human gastrointestinal tract. Dan. Med. Bull. 46, 183–196 (1999). pmid: 10421978
43. C. Holliger, G. Wohlfarth, G. Diekert, Reductive dechlorination in the energy metabolism of anaerobic bacteria. FEMS Microbiol. Rev. 22, 383–398 (1998). doi: 10.1111/ j.1574-6976.1998.tb00377.x
44. N. Koppel, J. E. Bisanz, M. E. Pandelia, P. J. Turnbaugh, E. P. Balskus, Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. eLife 7, e33953 (2018). doi: 10.7554/ eLife.33953; pmid: 29761785
45. H. J. Haiser et al., Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295–298 (2013). doi: 10.1126/science.1235872; pmid: 23869020
46. M. Boll, B. Schink, A. Messerschmidt, P. M. H. Kroneck, Novel bacterial molybdenum and tungsten enzymes: Three-dimensional structure, spectroscopy, and reaction mechanism. Biol. Chem. 386, 999–1006 (2005). doi: 10.1515/BC.2005.116; pmid: 16218872
47. R. A. Rothery, J. H. Weiner, Shifting the metallocentric molybdoenzyme paradigm: The importance of pyranopterin coordination. J. Biol. Inorg. Chem. 20, 349–372 (2015). doi: 10.1007/s00775-014-1194-6; pmid: 25267303
48. W. Zhu et al., Precision editing of the gut microbiota ameliorates colitis. Nature 553, 208–211 (2018). doi: 10.1038/ nature25172; pmid: 29323293
49. J. E. Bisanz et al., Illuminating the microbiome’s dark matter: A functional genomic toolkit for the study of human gut Actinobacteria. bioRxiv 10.1101/304840 (2018); accessed 18 April 2019]. doi: 10.1101/304840
50. A. Martínez-del Campo et al., Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. mBio 6, e00042–e15 (2015). doi: 10.1128/mBio.00042-15; pmid: 25873372
51. S. Torriani et al., Rapid detection and quantification of tyrosine decarboxylase gene (tdc) and its expression in gram-positive bacteria associated with fermented foods using PCR-based methods. J. Food Prot. 71, 93–101 (2008). doi: 10.4315/ 0362-028X-71.1.93; pmid: 18236668
52. S. C. Preissner et al., Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLOS ONE 8, e82562 (2013). doi: 10.1371/journal.pone.0082562; pmid: 24340040
53. J. Collins et al., Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature 553, 291–294 (2018). doi: 10.1038/nature25178; pmid: 29310122
54. P. Burkhard, P. Dominici, C. Borri-Voltattorni, J. N. Jansonius, V. N. Malashkevich, Structural insight into Parkinson’s disease treatment from drug-inhibited DOPA decarboxylase. Nat. Struct. Biol. 8, 963–967 (2001). doi: 10.1038/ nsb1101-963; pmid: 11685243
55. M. Sandler, R. D. Johnson, C. R. J. Ruthven, J. L. Reid, D. B. Calne, Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition. Nature 247, 364–366 (1974). doi: 10.1038/247364b0; pmid: 4817854
56. B. D. Wallace et al., Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010). doi: 10.1126/science.1191175; pmid: 21051639
57. M. Zimmermann, M. Zimmermann-Kogadeeva, R. Wegmann, A. L. Goodman, Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science 363, eaat9931 (2019). doi: 10.1126/science.aat9931; pmid: 30733391
58. G. Eisenhofer et al., Substantial production of dopamine in the human gastrointestinal tract. J. Clin. Endocrinol. Metab. 82, 3864–3871 (1997). doi: 10.1210/jcem.82.11.4339; pmid: 9360553
59. Z. S. Li, C. Schmauss, A. Cuenca, E. Ratcliffe, M. D. Gershon, Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: Analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J. Neurosci. 26, 2798–2807 (2006). doi: 10.1523/JNEUROSCI.4720-05.2006; pmid: 16525059
60. S. Dichtl et al., Dopamine is a siderophore-like iron chelator that promotes Salmonella enterica serovar typhimurium virulence in mice. mBio 10, e02624–e18 (2019). doi: 10.1128/ mBio.02624-18; pmid: 30723125
61. R. R. Scheline, R. T. Williams, J. G. Wit, Biological dehydroxylation. Nature 188, 849–850 (1960). doi: 10.1038/ 188849a0; pmid: 13747445
62. D. J. Sweeny et al., Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab. Dispos. 38, 1166–1176 (2010). doi: 10.1124/ dmd.110.032151; pmid: 20371637
63. N. Koppel, V. Maini Rekdal, E. P. Balskus, Chemical transformation of xenobiotics by the human gut microbiota. Science 356, eaag2770 (2017). doi: 10.1126/science.aag2770; pmid: 28642381